Gene Therapy: It’s Time to Talk about High-Dose AAV
Two deaths in a recent gene therapy trial raise questions about vector safety. How can we safely use vectors at high doses? Can we make high doses unnecessary?
An investigation by FDA regulators to determine whether this was related to the treatment with a high-dose AAV therapy as mentioned by the author of this article.
It's going to be a complicated issue and I believe it will not fade away at least in short to medium term...
ANP Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
